Tenidap is neuroprotective in a pilocarpine rat model of temporal lobe epilepsy

Chinese Medical Journal

Volumn 126, Issue 10, 2013, Pages 1900-1905

  Tang, Xing Hua ^a   Wu, Xun Yi ^a   Xu, Lan ^a   Fang, You Xin ^a   Wang, Jian Hong ^a   Zhu, Guo Xing ^a   Hong, Zhen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2 inhibitors; Temporal lobe epilepsy; Tenidap

Indexed keywords

CYCLOOXYGENASE 2; NEURON SPECIFIC NUCLEAR PROTEIN; PILOCARPINE; TENIDAP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE DISORDER; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DISEASE SEVERITY; EPILEPTIC STATE; HIPPOCAMPAL CA3 REGION; HISTOLOGY; IMMUNOCYTOCHEMISTRY; MALE; MONITORING; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; SIDE EFFECT; TEMPORAL LOBE EPILEPSY; WEIGHT REDUCTION;

ANIMALS; CYCLOOXYGENASE 2; EPILEPSY, TEMPORAL LOBE; INDOLES; MALE; NEUROPROTECTIVE AGENTS; PILOCARPINE; RATS; RATS, WISTAR;

EID: 84877867070     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122710     Document Type: Article

References (31)

1. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid inducedf seizure and neuronal cell death in the hippocampus. Brain Res 1999; 843: 118-129.
2. Lee B, Dziema H, Lee KH, Choi YS, Obrietan K. CRE-mediated transcription and COX-2 expression in the pilocarpine model of status epilepticus. Neurobiol Dis 2007; 25: 80-91.
3. Cole-Edwards KK, Bazan NG. Lipid signaling in experimental epilepsy. Neurochem Res 2005; 30: 847-853.
4. Kulkarni SK, Dhir A. Cyclooxygenase in epilepsy: from perception to application. Drugs Today (Barc) 2009; 45: 135-154.
5. Kunz T, Oliw EH. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur J Neurosci 2001; 13: 569-575.
6. Jung KH, Chu K, Lee ST, Kim J, Sinn DI, Kim JM, et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis 2006; 23: 237-246.
7. Polascheck N, Bankstahl M, Loscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol 2010; 224: 219-233.
8. Best L, Brown PD, Sener A, Malaisse WJ. Opposing effects of tenidap on the volume-regulated anion channel and K(ATP) channel activity in rat pancreatic beta-cells. Eur J Pharmacol 2010; 629: 159-163.
9. Holtman L, Van Vliet EA, Van Schaik R, Queiroz CM, Aronica E, Gorter JA. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res 2009; 84: 56-66.
10. Liu Y, Liu D, Printzenhoff D, Coghlan MJ, Harris R, Krafte DS. Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3. Eur J Pharmacol 2002; 435: 153-160.
11. Young CC, Stegen M, Bernard R, Muller M, Bischofberger J, Veh RW, et al. Upregulation of inward rectifier K+ (Kir2) channels in dentate gyrus granule cells in temporal lobe epilepsy. J Physiol 2009; 587: 4213-4233.
12. Xu L, Wu XY, Tang XH, Wang JH, Hong Z. Effect of Tenidap on expression of inwardly rectifying potassium channel 2.3 in hippocampus of chronic temporal lobe epileptic rats. Chin J Neurol (Chin) 2010; 43: 464-468.
13. Fouda HG, Avery MJ, Dalvie D, Falkner FC, Melvin LS, Ronfeld RA. Disposition and metabolism of tenidap in the rat. Drug Metab Dispos 1997; 25: 140-148.
14. Raedt R, Van Dycke A, Van Melkebeke D, De Smedt T, Claeys P, Wyckhuys T, et al. Seizures in the intrahippocampal kainic acid epilepsy model: characterization using long-term video- EEG monitoring in the rat. Acta Neurol Scand 2009; 119: 293-303.
15. Pernot F, Heinrich C, Barbier L, Peinnequin A, Carpentier P, Dhote F, et al. Inflammatory changes during epileptogenesis and spontaneous seizures in a mouse model of mesiotemporal lobe epilepsy. Epilepsia 2011; 52: 2315-2325.
16. Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008; 29: 142-160.
17. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer A M, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16: 413-419.
18. Shapiro LA, Wang L, Ribak CE. Rapid astrocyte and microglial activation following pilocarpine-induced seizures in rats. Epilepsia 2008; 49: 33-41.
19. Borges K, Gearing M, Mcdermott DL, Smith AB, Almonte AG, Wainer BH, et al. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp Neurol 2003; 182: 21-34.
20. Hashimoto K, Watanabe K, Nishimura T, Iyo M, Shirayama Y, Minabe Y. Behavioral changes and expression of heat shock protein hsp-70 mRNA, brain-derived neurotrophic factor mRNA, and cyclooxygenase-2 mRNA in rat brain following seizures induced by systemic administration of kainic acid. Brain Res 1998; 804: 212-223.
21. Kawaguchi K, Hickey RW, Rose ME, Zhu L, Chen J, Graham SH. Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus. Brain Res 2005; 1050: 130-137.
22. Bondeson J. Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review. Gen Pharmacol 1996; 27: 943-956.
23. Okada K, Yuhi T, Tsuji S, Yamashita U. Cyclooxygenase-2 expression in the hippocampus of genetically epilepsy susceptible El mice was increased after seizure. Brain Res 2001; 894: 332-335.
24. Desjardins P, Sauvageau A, Bouthillier A, Navarro D, Hazell A S, Rose C, et al. Induction of astrocytic cyclooxygenase-2 in epileptic patients with hippocampal sclerosis. Neurochem Int 2003; 42: 299-303.
25. Du P, Tang H Y, Li X, Lin H J, Peng W F, Ma Y, et al. Anticonvulsive and antioxidant effects of curcumin on pilocarpine-induced seizures in rats. Chin Med J 2012; 125: 1975-1979.
26. Kirchner T, Argentieri DC, Barbone AG, Singer M, Steber M, Ansell J, et al. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther 1997; 282: 1094-1101.
27. Lavigne P, Shi Q, Jolicoeur FC, Pelletier JP, Martel-Pelletier J, Fernandes JC. Modulation of IL-1beta, IL-6, TNF-alpha and PGE(2) by pharmacological agents in explants of membranes from failed total hip replacement. Osteoarthritis Cartilage 2002; 10: 898-904.
28. Aleo MD, Wang T, Giebisch G, Sanders MJ, Walsh AH, Lopez-Anaya A. Model development and analysis of tenidap-induced proteinuria in the rat. J Pharmacol Exp Ther 1996; 279: 1318-1326.
29. Pitkanen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009; 14: 16-25.
30. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 2010; 51: 1333-1347.
31. Zibell G, Unkruer B, Pekcec A, Hartz AM, Bauer B, Miller DS, et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009; 56: 849-855.